Myasthenia gravis

Three neurologists from Toronto’s Centre for Neuromuscular Diseases have analyzed the findings of various trials of rozanolixizumab (Rystiggo®), a monoclonal antibody directed against neonatal Fc receptors (anti-FcRn), in autoimmune myasthenia with anti-RACh or anti-MuSK antibodies. They conclude that : rozanolixizumab is effective, reducing pathogenic IgG by up to -78%, similar to plasma exchange; it also … [Read more]

A North American online study gathered 59 women who had 90 pregnancies in the decade following the diagnosis of autoimmune myasthenia : 62.2% of these happy events were planned, the remaining, unplanned pregnancies were accompanied by an increased risk of disease exacerbation (37.7% vs. 13.7%), hospitalization (26.5% vs. 11%) and maternal admission to intensive care … [Read more]

A multicenter retrospective study conducted in Italy on 213 patients with autoimmune myasthenia operated on between 2011 and 2021 for a thymoma, advanced stage (Masaoka-Koga III or IV) for 24 of them, shows that: 110 had an open thymectomy (sternotomy or lateral or posterolateral thoracotomy), the others a robot-assisted thymectomy; open surgery was associated with … [Read more]

Following an initial presentation at the 2021 American Academy of Neurology meeting, the final (and more moderate) results of the Vivacity-MG trial were published in the journal Neurology in January 2024 : 57 of the 68 participants completed 57 days of treatment with placebo or nipocalimab 5, 30 or 60 mg; the incidence of side-effects … [Read more]

Myasthenia gravis is included in the “precautions for use” of iodinated contrast products because of a possible worsening of the symptoms of the disease caused by their injection. After analysing the sometimes contradictory results of three retrospective studies, the Contrast Products Safety Committee of the European Society of Urogenital Radiology updated its recommendations on the … [Read more]

A Japanese consortium of clinicians reports the clinical and paraclinical data of a large series of patients diagnosed with anti-MuSK antibody-positive myasthenia gravis: 51 patients were included in the study from an initial sample of 1,710 patients with myasthenia gravis (3% of the total), two patients double-positive for MuSK protein and acetylcholine receptor were excluded beforehand, … [Read more]

A multicentre study conducted in Germany has provided a better understanding of the determinants of respiratory complications during acute attacks of myasthenia gravis: 12 centres took part in the study and pooled the clinical data of 197 patients, this corresponded to 217 acute episodes requiring mechanical ventilation in intensive care, 64% of patients had difficulty … [Read more]

Using the French National Health Data System (SNDS), the Stamina study analysed information on patients hospitalised for myasthenia gravis or on long-term care for this condition between 2008 and 2020. The results of the study show: a prevalence of the disease in France of 34.2 per 100,000 inhabitants (i.e. 22,979 patients) and an incidence of … [Read more]

A large international collaboration has reported 46 cases associated with maternal anti-fetal acetylcholine receptor antibodies (fRACh), the largest cohort ever described to date. The 30 mothers had anti-fRACh and anti-RACh antibodies, and half of them had not been diagnosed with myasthenia prior to pregnancy. There were seven terminations of pregnancy for severe congenital multiple arthrogryposis, … [Read more]